Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QNCX Quince Therapeutics, Inc.

Closed 10-09 16:00:00 EDT

31.73

+0.00

0.00%

High31.73	Low31.73	Vol0.00
Open31.73	D1 Closing31.73	Amplitude0.00%
Mkt Cap32.27M	Tradable Cap21.57M	Total Shares1.02M
T/O4.63M	T/O Rate0.00%	Tradable Shares679.70K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QNCX","market":"US","secType":"STK","nameCN":"Quince Therapeutics, Inc.","latestPrice":31.73,"timestamp":1791576000000,"preClose":31.73,"halted":8,"volume":0,"delay":0,"changeRate":0,"floatShares":679700,"shares":1017099,"eps":-90.925,"marketStatus":"Closed","change":0,"latestTime":"10-09 16:00:00 EDT","open":31.73,"high":31.73,"low":31.73,"amount":4631154.020087,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-90.925,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1792656000000},"marketStatusCode":5,"symbolChange":{"newSymbol":"IRLA","executeDate":"2026-10-12"},"adr":0,"listingDate":1557374400000,"exchange":"NASDAQ","adjPreClose":31.73,"volumeRatio":0},"requestUrl":"/m/hq/s/QNCX/wiki","defaultTab":"wiki","newsList":[{"id":"2674854384","title":"Quince Therapeutics Changes Name to IRulya Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2674854384","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674854384?lang=en_us&edition=fundamental","pubTime":"2026-10-09 20:32","pubTimestamp":1791549158,"startTime":"0","endTime":"0","summary":"Quince Therapeutics  said Friday it has changed its name to IRulya Therapeutics, effective later today.The company said its stock will begin trading on the Nasdaq Capital Market under the \"IRLA\" ticker on Monday.The name change follows the completion of Quince's merger with Orphai Therapeutics, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","LENZ","BK4007","IRLA","QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674851355","title":"Quince Therapeutics - Appoints Brigette Roberts as CEO Effective October 8, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2674851355","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674851355?lang=en_us&edition=fundamental","pubTime":"2026-10-09 20:04","pubTimestamp":1791547492,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nFWN45V13M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QNCX","IRLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674851358","title":"Quince Therapeutics - Common Stock to Trade Under Symbol 'Irla' on NASDAQ Effective Oct 12, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2674851358","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674851358?lang=en_us&edition=fundamental","pubTime":"2026-10-09 20:04","pubTimestamp":1791547480,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nFWN45V0YI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QNCX","IRLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674513538","title":"Quince Therapeutics - Changes Name to Irulya Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2674513538","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674513538?lang=en_us&edition=fundamental","pubTime":"2026-10-09 20:04","pubTimestamp":1791547480,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nFWN45V0YI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRLA","QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674859013","title":"Quince Therapeutics Appoints Brigette Roberts CEO in Management Overhaul","url":"https://stock-news.laohu8.com/highlight/detail?id=2674859013","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674859013?lang=en_us&edition=fundamental","pubTime":"2026-10-09 20:00","pubTimestamp":1791547222,"startTime":"0","endTime":"0","summary":"Quince Therapeutics appoints Brigette Roberts CEO in management overhaulQuince Therapeutics named Brigette Roberts as CEO; she previously led Orphai Therapeutics and served on Quince’s board.John Mili","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nNDLc0wSh2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCKT","IRLA","QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673065926","title":"Quince Therapeutics Holds Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2673065926","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673065926?lang=en_us&edition=fundamental","pubTime":"2026-10-07 04:58","pubTimestamp":1791320325,"startTime":"0","endTime":"0","summary":"Quince Therapeutics holds special shareholder meetingQuince Therapeutics held a special shareholder meeting on Oct. 6, 2026.Shareholders authorized issuance of common shares tied to conversion of Seri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDL9cmGxK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRLA","BK4139","QNCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672197117","title":"Quince Therapeutics Names Leone Patterson Audit, Compensation Committee Chair in Board Overhaul","url":"https://stock-news.laohu8.com/highlight/detail?id=2672197117","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672197117?lang=en_us&edition=fundamental","pubTime":"2026-10-02 19:31","pubTimestamp":1790940669,"startTime":"0","endTime":"0","summary":"Quince Therapeutics names Leone Patterson audit, compensation committee chair in board overhaulQuince Therapeutics disclosed conditional resignations from directors June Bray, David Lamond, Christophe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDLxklhw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1228905540.USD","LU2468319806.SGD","LU0211331839.USD","LU1064927863.SGD","LU0203345920.USD","LU1202635105.USD","LU1302929846.USD","LU1400636491.USD","LU1983299246.USD","LU0971552673.USD","SG9999001176.USD","GSK.UK","LU0321505439.SGD","LU1015430645.USD","LU1309081286.SGD","LU1481600234.SGD","SG9999001176.SGD","LU0161305163.EUR","INSM","IE00BQJZX424.USD","LU1400636657.SGD","IE0034235071.USD","LU0889565916.HKD","LU0306806265.USD","LU0203347892.USD","IE00BWDBJ516.SGD","LU0321505868.SGD","LU0985481810.HKD","LU0109981661.USD","LU0289739699.SGD","LU0058720904.USD","LU1670756490.USD","LU0971552830.HKD","IE00B3T34201.USD","LU0053671581.USD","LU0987226296.USD","BK5011","LU1228905037.USD","LU0557290698.USD","LU1035777561.USD","LU0225284248.USD","LU0545562505.USD","QNCX","LU0306807586.USD","LU1481599808.USD","LU1400636574.HKD","BK4139","LU0109394709.USD","LU1645745479.HKD","ZYME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671274384","title":"Leerink Partners Reaffirms Their Buy Rating on Quince Therapeutics (QNCX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671274384","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671274384?lang=en_us&edition=fundamental","pubTime":"2026-09-30 16:05","pubTimestamp":1790755522,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Quince Therapeutics yesterday and set a price target of $68.00. The company’s s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-reaffirms-their-buy-rating-on-quince-therapeutics-qncx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-reaffirms-their-buy-rating-on-quince-therapeutics-qncx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668896490","title":"Quince Therapeutics to Host Virtual KOL Event on PH-ILD, BOS Treatment Landscape and LAM-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2668896490","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668896490?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:01","pubTimestamp":1789646501,"startTime":"0","endTime":"0","summary":"Quince Therapeutics to host virtual KOL event on PH-ILD, BOS treatment landscape and LAM-001Quince Therapeutics will host a virtual KOL event on Sept. 28, 2026, from 12:30-2:00 p.m. ET.Discussion will","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDL8XCNJV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BGHQF748.EUR","NDAQ","BK4139","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4585","IE00BQXX3C00.GBP","IE00B3QW5Z07.USD","BK4588","IE00B64PRP62.GBP","LU0314104364.USD","QNCX","SG9999014021.USD","BK4112","IE00BQXX3F31.USD","LU2210149790.SGD","IE00BQXX3D17.EUR","IE00BKPKM429.USD","SG9999014005.SGD","LU2095319765.USD","IE00BN0W2V16.EUR","SG9999014039.USD","IE00BN0W2W23.USD","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664348523","title":"Quince Therapeutics Flags NASDAQ Noncompliance After Stockholders’ Equity Falls to ($35.32 Million)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664348523","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664348523?lang=en_us&edition=fundamental","pubTime":"2026-09-04 20:30","pubTimestamp":1788525055,"startTime":"0","endTime":"0","summary":"Quince Therapeutics flags Nasdaq noncompliance after stockholders’ equity falls to ($35.32 million)Quince received a Nasdaq notice on Aug. 31, 2026 for failing the $10 million minimum stockholders’ eq","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL1thnw3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662033321","title":"Quince Therapeutics President Charles Ryan to Exit Sept. 8","url":"https://stock-news.laohu8.com/highlight/detail?id=2662033321","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662033321?lang=en_us&edition=fundamental","pubTime":"2026-08-28 04:32","pubTimestamp":1787862765,"startTime":"0","endTime":"0","summary":"Quince Therapeutics President Charles Ryan to exit Sept. 8Quince Therapeutics President Charles Ryan will leave the company on Sept. 8, 2026.The decision was reached on Aug. 23, 2026.Disclaimer:This n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL8w8GRH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662732850","title":"Quince Therapeutics Announces Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2662732850","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662732850?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:32","pubTimestamp":1787661144,"startTime":"0","endTime":"0","summary":"Quince Therapeutics announces special shareholder meetingQuince Therapeutics set a special shareholder meeting for Oct. 6, 2026 via live webcast.Vote planned on issuing common stock tied to conversion","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nNDL8nGYqL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660870502","title":"Craig-Hallum bullish on Quince Therapeutics, initiates with a Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2660870502","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660870502?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:35","pubTimestamp":1787232939,"startTime":"0","endTime":"0","summary":"As previously reported, Craig-Hallum initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $68 price target The firm notes Orphai,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/craig-hallum-bullish-on-quince-therapeutics-initiates-with-a-buy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/craig-hallum-bullish-on-quince-therapeutics-initiates-with-a-buy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","LENZ","BK4007","QNCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660461386","title":"Quince Therapeutics : Leerink Partners Adjusts Target Price to $68 from $4 to Reflect 1-for-20 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2660461386","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660461386?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:53","pubTimestamp":1787050428,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F059:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QNCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660481587","title":"Quince Therapeutics Raises USD 115 Million in Private Placement of Series C Preferred Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2660481587","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660481587?lang=en_us&edition=fundamental","pubTime":"2026-08-17 18:27","pubTimestamp":1786962451,"startTime":"0","endTime":"0","summary":"Quince Therapeutics raises USD 115 million in private placement of Series C preferred sharesQuince Therapeutics priced a private placement, issuing 144,200 shares of Series C Non-Voting Convertible Pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL1W1ky:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659147805","title":"Quince Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659147805","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659147805?lang=en_us&edition=fundamental","pubTime":"2026-08-14 22:11","pubTimestamp":1786716669,"startTime":"0","endTime":"0","summary":"Quince Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings SummaryQuince Therapeutics, Inc.QNCX.OQreported a quarterly adjusted loss of $12.31 per share for the quarter ended J","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL8N44B100:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659499031","title":"Quince Therapeutics Q2 Net Loss Widens on Acquisition Charges","url":"https://stock-news.laohu8.com/highlight/detail?id=2659499031","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659499031?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:18","pubTimestamp":1786709883,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Q2 net loss widens on acquisition chargesOverviewUS biopharmaceutical developer completed Orphai acquisition, adding LAM-001 to late-stage pulmonary pipelineCompany closed $115 mln","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0EC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","PULM","BK4139","BK4007","LQDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659146722","title":"Press Release: Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659146722","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659146722?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:01","pubTimestamp":1786708860,"startTime":"0","endTime":"0","summary":"placement financing. On May 18, 2026, Quince completed a stock-for-stock. merger to acquire Orphai, a clinical-stage biotechnology company,bringing Orphai's lead program, LAM-001, an inhaled formulation of. rapamycin , into the pipeline. LAM-001 is being. developed for the treatment of serious, underserved pulmonary diseases,.Concurrent with the acquisition, Quince entered into a definitive. agreement for a private placement financing with gross upfront proceeds. of $115 million, yielding net proceeds of $103.6 million after deducting. placement agent and other offering expenses of $11.4 million, for the. purchase of shares of Series C non-voting convertible preferred stock and. up to an additional $83 million upon the exercise of warrants (including","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","LENZ","BK4539","ATS","BK4139","BK4007","SAPH","QNCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657108216","title":"Quince Therapeutics, Inc. Expected to Post a Loss of $17.88 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657108216","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657108216?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:01","pubTimestamp":1786100494,"startTime":"0","endTime":"0","summary":"Quince Therapeutics, Inc. <QNCX.OQ> expected to post a loss of $17.88 a share - Earnings PreviewQuince Therapeutics, Inc.QNCX.OQQNCX.Ois expected to  show no change in quarterly revenue when it report","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4440XH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656916773","title":"Quince Therapeutics - Brigette Roberts Conditionally Appointed as Chief Executive Officer - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2656916773","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656916773?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:52","pubTimestamp":1785531128,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X2NT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.quincetx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.0763},{"period":"3month","weight":0.7114},{"period":"6month","weight":0.1665},{"period":"1year","weight":-0.9142},{"period":"ytd","weight":-0.9526}],"compareEarnings":[{"period":"1week","weight":-0.0115},{"period":"1month","weight":0.0097},{"period":"3month","weight":0.029},{"period":"6month","weight":0.0855},{"period":"1year","weight":0.1456},{"period":"ytd","weight":0.1278}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.091321},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.101646},{"month":3,"riseRate":0.428571,"avgChangeRate":0.087035},{"month":4,"riseRate":0.571429,"avgChangeRate":-0.03031},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.092353},{"month":6,"riseRate":0.625,"avgChangeRate":0.135399},{"month":7,"riseRate":0.375,"avgChangeRate":-0.03183},{"month":8,"riseRate":0.5,"avgChangeRate":0.077894},{"month":9,"riseRate":0.5,"avgChangeRate":0.006209},{"month":10,"riseRate":0.375,"avgChangeRate":-0.040549},{"month":11,"riseRate":0.571429,"avgChangeRate":0.199459},{"month":12,"riseRate":0.285714,"avgChangeRate":0.079276}],"exchange":"NASDAQ","name":"Quince Therapeutics, Inc.","nameEN":"Quince Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Quince Therapeutics, Inc.(QNCX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Quince Therapeutics, Inc.,QNCX,Quince Therapeutics, Inc.股票,Quince Therapeutics, Inc.股票老虎,Quince Therapeutics, Inc.股票老虎国际,Quince Therapeutics, Inc.行情,Quince Therapeutics, Inc.股票行情,Quince Therapeutics, Inc.股价,Quince Therapeutics, Inc.股市,Quince Therapeutics, Inc.股票价格,Quince Therapeutics, Inc.股票交易,Quince Therapeutics, Inc.股票购买,Quince Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Quince Therapeutics, Inc.(QNCX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction